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CD13/aminopeptidase N is a membrane-bound metalloproteinase implicated in human cytomegalovirus (HCMV) infection and
pathogenesis. Anti-CD13 antibodies can neutralize HCMV infectivity, and HCMV viremia after bone marrow transplantation induces anti-
CD13 autoantibodies which correlate with development of chronic graft vs. host disease. We examined whether murine CD13/APN was
similarly implicated in murine cytomegalovirus (MCMV) disease. MCMV infection did induce anti-CD13 antibodies in mice in a strain-
specific manner. ICR and 129S mice developed high titers of anti-CD13 antibodies and anti-MCMV antibodies after MCMV infection,
whereas CBA and CBAxC57BL/6 f1 hybrid mice produced antibodies against MCMV only. Unlike HCMV, no evidence was found for a
correlation between host cell CD13/APN expression and infection, or for the presence of CD13/APN on MCMV particles, although APN
inhibitors decreased MCMV plaque formation. Reproduction of CD13/APN autoantibody production in the murine system should make it
possible to determine if these antibodies contribute to CMV pathogenesis.
D 2005 Elsevier Inc. All rights reserved.
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Cytomegaloviruses are beta-herpesviruses which estab-
lish life-long infections in their hosts. Several findings have
implicated CD13, also known as aminopeptidase N (APN),
in human cytomegalovirus (HCMV) infection and patho-
genesis. In a series of bone marrow transplant patients,
CD13/APN-specific autoantibodies were found only in
patients with confirmed CMV disease after transplant and
were highly associated with later development of chronic
graft vs. host disease (cGVHD) (Soderberg et al., 1996a,
1996b). Patients seropositive for CMV but negative for the
presence of virus did not develop anti-CD13/APN anti-
bodies or cGVHD (Soderberg et al., 1996b). On the
molecular level, several groups have shown that human
CMV incorporates host cell proteins, one of which is CD13/
APN, into its viral envelope (Homman-Loudiyi et al., 2003;0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.01.028
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E-mail address: kasmanl@musc.edu.Michelson et al., 1989; Naucler et al., 1996; Wright et al.,
1995). Some monoclonal antibodies raised against CD13/
APN can neutralize human CMV viral particles, and
immunoblots of purified human CMV virions detect
CD13/APN (Soderberg et al., 1993a). When viral particles
are labeled with immunogold-anti-CD13 antibodies, the
immunogold particles are later seen on the surface of
infected cells (Giugni et al., 1996). Consistent with viral
sequestration of CD13/APN, cell surface CD13/APN is
down-regulated after human CMV infection in fibroblasts
(Phillips et al., 1998). Association of CD13/APN with the
viral particle has been suggested as a mechanism for the
generation of anti-CD13/APN antibodies after CMV infec-
tion by autoimmunization (Naucler et al., 1996). That virus-
associated CD13/APN is essential for HCMV infection is
suggested by anti-CD13 antibody inhibition of infection
(Soderberg et al., 1993a); however, human neuroblastoma
cells lacking CD13 expression were susceptible to HCMV
infection (Watanabe, 1998), and recently the epidermal
growth factor receptor has been shown to be an important
mediator of HCMV entry into cells (Wang et al., 2003).2005) 1–9
Fig. 1. MCMV infection induces anti-CD13 antibodies in susceptible strains
of mice. Groups of four ICR, CBA/J, B6/CBA f1 hybrids, and interferon
gamma receptor knock out mice on a 129S background were infected by
intraperitoneal injection with 105 PFU MCMV. Sera collected 14 days post-
infection were assayed in duplicate at a 1:10 dilution for anti-MCMV (gray
bars) and anti-CD13 (black bars) antibodies by ELISA. Figure is
representative of two similar experiments. Dashed line indicates mean
antibody response in mock-infected mice.
L.M. Kasman / Virology 334 (2005) 1–92CD13/APN is a membrane-bound metalloproteinase
widely expressed on mammalian cells including monocytes,
macrophages, endothelial cells, epithelial cells, and fibro-
blasts (Curnis et al., 2002; Phillips et al., 1998; Plakidou-
Dymock et al., 1993; Riemann et al., 1999). It exists as a
heavily glycosylated homodimer with a constitutively active
proteinase activity external to the plasma membrane
(Riemann et al., 1999). In addition to numerous tissue-
specific functions, CD13/APN serves as a major receptor for
type I coronaviruses (Breslin et al., 2003; Yeager et al.,
1992), including possibly the SARS virus (Yu et al., 2003).
More recently, CD13/APN has been shown to be an
important mediator of angiogenesis when expressed on
endothelial cells of nascent blood vessels (Bhagwat et al.,
2001). Antibodies raised against CD13/APN and inhibitors
of aminopeptidase activity both block angiogenesis in
models of neovascularization (Pasqualini et al., 2000). This
may have significance with regard to CMV, since CMV
infection is associated with many chronic vascular diseases
(Borchers et al., 1999; Hamamdzic et al., 2002; Nieto et al.,
1996; Pandey and LeRoy, 1998). CMV-induced anti-CD13/
APN antibodies may represent one mechanism by which the
virus initiates vascular pathology.
Like most herpesviruses, cytomegaloviruses are species
specific, but the link between CMV and vascular disease
seen in humans has been reproduced repeatedly in mice
infected with murine cytomegalovirus (Berencsi et al., 1998;
Hamamdzic et al., 2001; Hummel et al., 2001; Presti et al.,
1998). Therefore, in this study, we have examined whether
CD13/APN is also implicated in MCMV infections in mice.Results
MCMV infection induces anti-CD13/APN antibodies in a
strain-specific manner
Four mouse strains were tested for the induction of
MCMV and CD13/APN immunity after MCMV infection.
These strains, CBA, CBAxC57BL/6 f1 hybrids, ICR, and
129S mice deficient in the interferon gamma receptor
(IFNgR/), vary in their H-2 haplotype and in their
reported resistance to MCMV infection. Groups of 4–6
animals of each of these strains were infected with 105 PFU
MCMV by IP injection, which is a sublethal dose in adult
animals for all strains. Serum was collected after 14 days and
analyzed by ELISA for IgG antibodies against MCMV and
mouse CD13/APN. All strains had similar levels of IgG
antibodies directed against MCMV (Fig. 1). However, anti-
CD13/APN antibodies were detected only in the sera from
ICR and 129S-IFNgR/mice, and no detectable antibodies
against CD13 were found in sera from CBA or B6 hybrid
mice. Anti-CD13 antibodies in humans were reported in
people who developed HCMV viremia while in an immuno-
compromised state. In order to test whether an immunocom-
promised state would be associated with induction of higherlevels anti-CD13 antibodies inmice, cyclosporine Awas used
to induce an immunocompromised state in ICR mice. Three
groups of 6 ICRmice were treated with either cyclosporine A
alone, cyclosporine A and 105 PFU MCMV, or 105 PFU
MCMV +mock cyclosporine A injections. Mice treated with
cyclosporine A and MCMV had increased signs of illness
over those given MCMValone (not shown). However, levels
of antibodies to both MCMV and CD13 were not signifi-
cantly different between the two groups (Fig. 2).
Cell surface APN activity and MCMV susceptibility
To investigate whether expression of murine CD13/APN
correlates with MCMV susceptibility as reported for HCMV
(Soderberg et al., 1993a, 1993b), five murine cell lines were
characterized with respect to MCMV progeny production
and cell surface aminopeptidase N/CD13 activity. NIH 3T3,
3T12, and primary mouse embryonic fibroblasts (MEF) are
all fibroblast in phenotype. Py-41 and SVEC-4 cells are
mouse endothelial cell lines immortalized by the polyoma T
antigen and the SV40 T-antigen, respectively (Dubois et al.,
1991; O’Connell and Edidin, 1990). In an assay of MCMV
progeny production after inoculation at low multiplicity of
infection, marked differences were seen between cell lines
in susceptibility to productive MCMV infection (Fig. 3A).
Peak MCMV titers in supernatants from the three fibroblast
lines were close to 106 PFU/ml, while SVEC-4 cells
produced 105 PFU/ml, and Py-41 cells produced less than
1000 PFU/ml. Similar relative results were seen in a plaque
assay on the five cell lines (Fig. 4).
In contrast to human cells, attempts to compare CD13/
APN expression on murine cell lines by immunological
methods were unsuccessful. Two commercially available
antibodies specific for murine CD13/APN failed to recog-
nize any proteins on Western blotted cell extracts (not
shown). Immunofluorescent flow cytometry staining of cell
surface proteins with antibody R3-242 conjugated to
phycoerythrin showed that CD13/APN was present on both
endothelial and fibroblast cells. However, relative expression
Fig. 2. Effect of cyclosporine A treatment on anti-CD13 antibody induction
by MCMV infection. Sera from female ICR mice were analyzed for anti-
MCMV (gray bars) and anti-CD13 (black bars) IgG antibodies by ELISA.
Groups of 6 mice were injected with (1) cyclosporine A (CsA) once daily for
15 days, (2) diluent once daily for 15 days and inoculation with 105 pfu
MCMV-lacZ on day 2, (3) CsA daily for 15 days and an equivalent amount
of uninfected salivary gland extract on day 2. All treatments were by
intraperitoneal injection. Sera were collected on day 15, diluted 1:10 in
saline, and analyzed in duplicate. Results are expressed as fold increase in
antibody levels relative to the mean response of mice treated with CsA alone.
Fig. 3. Characterization of five murine cell lines with respect to MCMV
progeny production and cell surface aminopeptidase N/CD13 activity. (A)
Monolayers of murine endothelial cell lines Py-41 and SVEC-4, and murine
fibroblast cell lines 3T3 and 3T12, and primary embryonic fibroblasts
(MEF), were infected with salivary gland-derived MCMV-lacZ at an MOI
of 0.1. Aliquots of supernatant collected approximately every 24 h were
tittered on 3T3 fibroblasts. Data shown are combined results of two
independent experiments. (B) Measurement of cell surface aminopeptidase
N activity by ala-p-nitroalanine cleavage. Actively growing cells of each
type were plated at four different densities 16 h prior to incubation with
colorimetric APN substrate ala-p-nitroalanine. Each data point is the
average of absorbance readings of 6 wells after 3-h incubation at 37 8C.
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an alternative to immunological techniques was used.
To quantitate cell surface CD13/APN, APN enzymatic
activity was measured by a standard procedure using the
colorimetric substrate, ala-p-nitroanalide hydrochloride
(Plakidou-Dymock et al., 1993). To determine the linearity
of the assay with adherent cells, Py-41, SVEC-4, 3T3, 3T12,
and MEF cells were plated at densities of 5000, 10,000,
20,000, and 40,000 cells/well and incubated 18 h later as
adherent monolayers with APN substrate. Substrate con-
version was directly proportional to the number of cells in
all cell lines (Fig. 3B), with slight decreases at higher
densities as expected. Cells were plated at 10,000 cells/well
in 96-well plates for subsequent assays. To compare
amounts of cell-surface CD13/APN exposed to MCMV in
a standard inoculation with subsequent plaque formation,
parallel sets of 6 wells of each cell type were assayed for
APN enzyme activity, or inoculated with MCMV-lacZ and
incubated a further 48 h, followed by staining and counting
of plaques. Three dilutions of MCMV-lacZ virus were used
in three sets of 6 wells to detect the range of susceptibilities
observed. There was no correlation between CD13/APN
expression and MCMV plaque formation (Fig. 4). CD13/
APN enzyme activity was similar on all five cell lines
whereas plaque formation and progeny virus production
were markedly different, especially between endothelial and
fibroblast cells. Whether or not CD13/APN is necessary for
MCMV infection cannot be determined from this experi-
ment since none of the murine cell lines tested were
negative for CD13/APN, however, CD13 expression is
clearly not sufficient for productive MCMV infection of Py-
41 endothelial cells.
APN inhibitors reduce MCMV infection
EDTA and 1,10-phenanthroline monohydrate are both
APN inhibitors which act by chelating divalent metals. Ateffective concentrations, both have the effect of causing
adherent cells, such as 3T3 cells, to lift. Therefore, cells
were purposely incubated with MCMV-lacZ virus in
suspension in the presence or absence of APN inhibitor.
After 1-h incubation, cells were washed clean of unbound
virus and inhibitor and plated. Plaques visualized at 48 h
post-infection with X-Gal were counted in 6 parallel wells/
treatment. Both EDTA and 1,10-phenanthroline signifi-
cantly decreased the number of plaques formed on treated
cells in a dose-dependent manner (Fig. 5A). Exposure to
concentrations of 1,10-phenanthroline above 1.5 mM or
EDTA above 5 mM for 1 h killed 3T3 cells. In contrast,
when virus was exposed to the same inhibitor concen-
trations for 30 min prior to dilution and inoculation of cells,
Fig. 4. MCMV susceptibility does not correlate with cell surface amino-
peptidase N/CD13 activity. Five murine cell lines (Py-41, SVEC-4, 3T3,
3T12) and primary embryonic fibroblasts (MEF) were each seeded into
wells of a 96-well plate at 10,000 cells/well. After being allowed to adhere
overnight, six wells of each cell type were immediately assayed for cell
surface APN activity, and parallel wells of each cell type were exposed to
MCMV-lacZ virus. After 2-h incubation with virus, inoculum was replaced
with fresh medium. Two days later, plaques were visualized by X-Gal
overlay. The titer (light bars) is expressed as mean plaques per well.
Relative APN activity (dark bars) is indicated in absorbance units on the
right y-axis. The figure is representative of two identical experiments.
Fig. 5. APN inhibitors reduce MCMV infection, but not virus viability. (A)
NIH 3T3 cells (6  104) were incubated in suspension with MCMV-lacZ
plus or minus APN inhibitors (10 mM, 5 mM, 1 mM or 0.1 mM EDTA, or
3 mM, 1.5 mM, 0.5 mM, or 0.17 mM 1,10-phenanthroline) or antibodies
(R3-242, sc-15360) as indicated. After 30 min at 37 8C, cells were washed
and resuspended in complete medium, and seeded at 104 cells/well into 6
wells of a 96-well plate. Plaques were visualized in each well by X-Gal
overlay 72 h post-infection. ++ Indicates cytotoxic inhibitor concentration.
* Indicates a significant difference from untreated control. (B) Virus
pretreatment with APN inhibitors: 105 PFU MCMV-lacZ were incubated
with inhibitors or anti-CD13 antibodies as indicated for 30 min, diluted
300-fold, and used to infect NIH 3T3 cells (6  104/100 Al) in suspension.
Plaques were visualized as in A. A representative of three similar
experiments is shown.
Table 1
APN activity in MCMV virus preparation
APN activity (substrate
cleaved/mg protein)
BBMV (Amol/min) 53.7
Uninfected salivary gland homogenate
(Amol/min)
3.0
MCMV-infected salivary gland homogenate
(Amol/min)
2.8
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MCMV particles themselves were not dependent on metal-
loproteinase activity for stability or activity (Fig. 5B).
Effect of anti-CD13/APN antibody on MCMV infection in
vitro
CD13/APN has been detected with antibodies in HCMV
viral envelopes and some anti-CD13/APN antibodies
neutralize human CMV and prevent infection in vitro
(Giugni et al., 1996). Both anti-murine CD13/APN anti-
bodies were tested for their ability to block MCMV
infection of NIH3T3 cells. Neither preincubation of anti-
body with virus nor antibody with host cells reduced plaque
formation (Figs. 5A and B). Since not all CD13/APN
epitopes give rise to neutralizing antibodies of HCMV
(Giugni et al., 1996), this did not rule out a role for APN in
MCMV infection. Strangely, the presence of antibody R3-
242 during infection significantly enhanced the number and
size of plaques formed on NIH3T3 cells (Fig. 5A), while
antibody H-300 had a similar effect when preincubated with
virus (Fig. 5B). Although antibody-dependent enhancement
of viral infection is well documented, it generally requires
antibodies from the same species as the host cells and
depends on Fc or complement receptor expression of the
host cell (Tirado and Yoon, 2003). R3-242 and H-300 are rat
and rabbit antibodies, respectively, and NIH 3T3 cells are
not known to express Fc receptors.
Two other methods were used to attempt to detect APN
incorporation into MCMV viral particles. APN activity
assays of salivary gland-derived virus vs. uninfected
salivary gland supernatants were compared and found to
be identical when normalized for protein content (Table 1).
In addition, salivary gland-derived MCMV, tissue culture-
derived MCMV, relevant uninfected control extracts, andmurine brush border membrane vesicles (BBMV) were
spotted onto nitrocellulose at several dilutions and probed
with antibody R3-242. The antibody readily detected an
80-fold dilution of BBMV, while failing to detect any
protein in the viral or control preparations at any dilution
(data not shown). In summary, no evidence for incorpo-
ration of CD13/APN into MCMV viral envelopes was
found.
Fig. 6. Cell surface APN activity is not significantly altered by MCMV
infection. Parallel wells of each cell line were mock infected (gray bars) or
infected with MCMV-lacZ at an MOI of 10 (black bars). After 18 h of
infection, cell surface APN activity was measured by ala-p-nitroalanine
cleavage. Addition of APN inhibitor 1,10-phenanthroline (striped bars)
with substrate was used as a positive control.
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by MCMV infection
Human CMV has been reported to reduce CD13/APN
expression in infected human fibroblasts approximately
30% within 24 h of infection, as determined by immuno-
fluorescence staining and APN activity assays. Expression
is further reduced to up to 50% over the next 2–3 days of
infection and appears to be due to ER retention and
degradation of the CD13 protein (Phillips et al., 1998). To
determine if MCMV has a similar effect on murine CD13/
APN, cells from all five murine cell lines were assayed for
APN activity 18 and 72 h after infection. Cells were infected
with an MOI of approximately 20, or mock infected with an
equivalent concentration of salivary gland homogenate from
uninfected mice. In contrast to human fibroblasts, all three
mouse fibroblast lines had slightly (10–30%) increased
APN cell surface activity 18 h after infection, while mouse
endothelial cell lines Py-41 and SVEC-4 had slightly (3–
9%) decreased APN activity (Fig. 6). At 72 h, cell death was
apparent in all infected wells, and APN activity was reduced
compared to mock-infected wells, however, APN activity
per well was increased compared to 18 h post-infection in
all cases due to increases in cell number (not shown). Whole
cell ELISA gave similar results, except that differences
between infected and non-infected cells were even smaller
(not shown). Therefore, unlike human CMV infection,
MCMV infection seems to have only a small effect if any
on CD13/APN expression in fibroblasts and endothelial
cells, which varies according to cell type.Discussion
In agreement with previous reports that human CMV
infection induces anti-CD13/APN antibodies in immuno-compromised individuals, we found that murine CMV
induced antibodies against murine CD13/APN in suscep-
tible strains of mice. However, treatment of susceptible mice
with the immunosuppressant Cyclosporine A did not
significantly increase anti-CD13/APN antibody production,
suggesting that immunosuppression is not necessary for
induction of these autoantibodies. Whether immunocompe-
tent humans can develop anti-CD13 antibodies after CMV
infection has not been investigated to our knowledge.
The strain producing the highest ratio of anti-CD13 to
anti-MCMV antibodies was 129S-IFNgR/ which has
been used as a model of persistent CMV infection because
the mice actively shed virus for at least 6 months after
infection (Presti et al., 1998). In contrast, CBA and CBA/B6
hybrids are known to be genetically resistant to MCMV-
induced mortality. MCMV resistance in mice is determined
largely by the gene cmv1, which encodes Ly49H, an NK
cell receptor which is activated by the MCMV protein m157
(Arase et al., 2002; Lee et al., 2002; Swihart et al., 1995).
MCMV-resistant mouse strains have peak spleen viral titers
that are 2–3 logs lower and LD50 doses that are 1–2 logs
higher than susceptible strains. CBA and C57BL/6 mice
express Ly49H on their NK cells and are resistant whereas
129S mice do not express Ly49H and are susceptible. The
ICR mice were not genotyped for cmv1 and were
intermediate in their susceptibility to MCMV morbidity, as
well as autoantibody production. This suggests that high
spleen titers may be associated with development of anti-
CD13 antibodies. MHC type does not seem to be correlated
with anti-CD13 antibody production in our experiments,
since the haplotype H-2b is shared by both productive 129S
and non-productive C57BL/6 hybrid strains.
In the human system, it has been proposed that anti-
CD13/APN antibodies occur as a result of autoimmuniza-
tion by CD13/APN incorporated into HCMV viral enve-
lopes. We were unable to find evidence of CD13/APN
incorporation into MCMV viral particles, but this may be
due to the limited variety of anti-CD13 antibodies available
for the murine system. Neither antibody tested was able to
detect CD13/APN on Western blots, and sc-15360 failed to
detect CD13/APN even in native BBMV containing APN
readily detected at a 1:80 dilution by antibody R3-242. It is
possible that a more comprehensive array of anti-murine
CD13/APN antibodies would have detected CD13/APN in
MCMV particles or have been able to neutralize MCMV
infectivity, however, APN enzymatic assays also failed to
detect a difference between virus and control lysates. Cell-
surface CD13/APN also did not correlate with MCMV
susceptibility. And while inhibitors of APN enzyme activity
did reduce MCMV plaque formation, the inhibitors used are
not especially specific for APN. Taken together, a role for
CD13/APN as an entry mediator for MCMV seems
unlikely.
Virus-induced autoantibodies, including anti-endothelial
cell and anti-phospholipid antibodies following cytomega-
lovirus infections, have been demonstrated before in both
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Khairullah, 1997; Fairweather et al., 1998; Hebart et al.,
1996; Hiemstra et al., 2001; Lipes et al., 2002; Lunardi et
al., 2000). With regard to the mechanisms of their
induction, it has been proposed that these antibodies are
directed against viral antigens which by coincidence
resemble host cellular proteins (molecular mimicry), or
that virus-induced tissue damage results in immunological
processing and recognition of self-antigens normally
sequestered from immune surveillance (Lawson, 2000;
Naucler et al., 1996). In this study, several factors argue
against a simple case of molecular mimicry. Although
human and mouse CD13/APN are 76% identical at the
amino acid level (Chen et al., 1996), HCMV and MCMV
share less homology, CD13/APN is glycosylated and
genetically polymorphic (Vijgen et al., 2004; Wentworth
and Holmes, 2001), and predicted MHC presentable
peptides differ with MHC haplotype and species. There-
fore, the likelihood of a single epitope common to both
hosts, both viruses, and presentable by several MHC types
seems small. Determination of the CD13/APN epitopes
recognized by the sera of different mouse strains is
currently underway and may allow identification of a viral
antigen inducer if molecular mimicry is leading to the
production of anti-CD13/APN antibodies.
Immunological processing of self-antigens as a result of
virus-induced tissue damage is more difficult to examine.
The association of CD13/APN autoantibodies with con-
ditions favoring high in vivo titers is consistent with this
mechanism. However, CD13/APN cannot credibly be
described as a sequestered self-antigen in that it is normally
expressed on the surface of numerous cell types throughout
the body and is present in normal serum (Kawai et al.,
2001). Therefore, neither of the general mechanisms thought
to give rise to virus-induced autoantibodies seems likely in
the case of MCMV-induced CD13/APN antibodies.
CMV seropositivity has long been associated with a
variety of vasculopathies including atherosclerosis and
systemic sclerosis (Borchers et al., 1999; Hamamdzic et
al., 2002; Nieto et al., 1996; Pandey and LeRoy, 1998).
CMV infection has also long been recognized as a serious
complication of bone marrow and solid organ transplanta-
tion because of vascular sequelae (Borchers et al., 1999;
Matthes-Martin et al., 1998). CMV viremia after bone
marrow transplant is associated with a significant increase in
chronic graft vs. host disease (cGVHD), which shares many
features in common with the autoimmune disease sclero-
derma, and begins as an inflammation and destruction of
small blood vessels (Pandey and LeRoy, 1998). CMV
viremia after solid organ transplant results in exacerbation of
transplant vascular sclerosis leading to chronic graft
rejection (Borchers et al., 1999). The mechanism(s) by
which CMV produces these negative outcomes is not
understood, however, reduction of viral titers with anti-viral
drugs decreases cGVHD, CMV-associated rejection, and
vascular stenosis (Koskinen et al., 1999; Matthes-Martinet al., 1998). Autoantibodies targeting an angiogenic factor
such as CD13/APN may be one mechanism by which CMV
could mediate these effects. The two mouse strains found to
produce anti-CD13/APN antibodies in this study are also the
strains most susceptible to CMV-induced vascular disease
(Berencsi et al., 1998; Hamamdzic et al., 2001; Presti et al.,
1998). The fact that CMV induction of anti-CD13/APN
antibodies is now reproduced in mice should make it
possible to examine whether such antibodies play a part in
CMV-induced vascular pathology.Materials and methods
Cells, medium, antibodies, FACS, immunoblotting
SVEC-4, NIH 3T3, and NIH 3T12 cells were obtained
from the ATCC (Rockville, MD) and grown as recommen-
ded. Mouse embryo fibroblasts were prepared from Balb/c
mouse embryos as described (Brune et al., 1999). Py-41
cells were generously provided to our lab by V.L. Bautch
(University of North Carolina, Chapel Hill, NC) and
propagated on gelatin-coated plates (Biocoat, Becton Dick-
enson) in low glucose DMEM + 10% fetal calf serum
(Dubois et al., 1991). All cells were grown in medium
containing Gibco antibiotic–antimycotic solution (Invitro-
gen, Inc.). Two anti-murine CD13 antibodies were used: R3-
242, a rat anti-mouse monoclonal (Research Diagnostics,
Inc.), and sc-15360, a rabbit IgG (Santa Cruz Biotechnolo-
gies, Inc.).
Virus and plaque assays
A recombinant murine cytomegalovirus expressing the
Escherichia coli lacZ gene (RM461), generously provided
by Edward Mocarski (Stanford University), was used in all
experiments. This virus expresses lacZ mid to late infection
so that the enzyme accumulates throughout infection
(Stoddart et al., 1994). Salivary gland passaged virus was
prepared as described previously (Hamamdzic et al., 2001)
and titered on 3T3 cells. Plaque assays were performed in
96-well plates. Briefly, NIH 3T3 cells were plated the day
before the assay at 104 cells/well. Dilutions of virus were
made in minimal essential medium containing 0.1% porcine
gelatin, and 20 Al diluted virus/well was incubated with cells
at 37 8C for 2 h. Inoculum was aspirated and cells covered
with 100 Al/well 0.6% methylcellulose in complete medium.
After incubation for 48–72 h, 100 Al 10% neutral-buffered
formalin was added to each well for 10 min, followed by
three washes with phosphate-buffered saline to remove
methylcellulose. Plaques were visualized by overlay with X-
Gal (5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside)
and counted under a dissecting scope. Inoculations of mice
were by intraperitoneal injection of salivary gland-passaged
virus in a volume of 0.2 ml using minimal essential medium
as a diluent.
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Cyclosporine A was purchased from LC laboratories
(Woburn, MA) and 14 mg was solubilized in 0.5 ml 100%
ethanol and 0.2 ml Tween 80, then diluted to 2 mg/ml in
PBS for injection. Ethylenediaminetetraacetic acid (0.5 M
solution, pH 8.0) was purchased from GibcoBRL (Cat. No.
15575-038). 1,10-Phenanthroline monohydrate (P 9375)
and l-alanine-p-nitroanilide hydrochloride were purchased
from Sigma.
Mice
CBA, CBA/C57BL6 f1 hybrids, and 129S IFNgR/
mice were obtained from Jackson Laboratories (Bar Harbor,
Maine). ICR mice were purchased from Harlan Laborato-
ries. All experiments described in this study conform with
bThe guide for the Care and Use of Laboratory AnimalsQ
published by the US National Institutes of Health (NIH
Publication No. 85-23, revised 1996) and were approved by
the MUSC institutional committee for the care and use of
laboratory animals. Food and water were provided ad
libitum. All mice were housed in hepa-filtered cages in
the approved animal facility and monitored daily.
Crude aminopeptidase N preparation
To prepare murine CD13, small intestines from nine ICR
mice were dissected free of mesenteric fat and flushed clean
with cold saline. The drained tissue was homogenized in 9
volumes cold sucrose buffer (2 mM Tris, pH 6.8, 50 mM
sucrose) with a Tissumizer SDT-1810 (Tekmar, Cincinnati
OH) for 1 min keeping the tube on ice. Brush border
membrane vesicle formation was induced by adding CaCl2
to a final concentration of 10 mM and stirring continuously
for 15 min at 4 8C. Debris was pelleted by centrifugation at
4000  g for 10 min. BBMVs were pelleted by
centrifugation of the supernatant for 30 min at 27,000  g
at 4 8C. BBMVs were resuspended in a small volume of
sucrose buffer and stored at 80 8C. Gut APN has been
shown to be serologically identical to CD13/APN expressed
in splenocytes and macrophage (Riemann et al., 1999).
Aminopeptidase N activity assays
Aminopeptidase N activity assays were performed by
incubating living adherent cells at 37 8C in phosphate-
buffered saline (pH 7.2) containing 6 mM alanine-p-
nitoanilide hydrochloride. Absorbance was read at 1-h
intervals at 405 nm.
ELISA
ELISAs were performed on Reacti-Bind maleic anhy-
dride activated clear 96-well plates (Pierce, Rockford, IL).
Viral antigen for ELISA was intact MCMV grown in tissueculture and prepared by ultracentrifugation through sucrose
by standard protocol (Brune et al., 1999). The partially
purified virus was diluted in phosphate-buffered saline to a
protein concentration of 10 mg/ml and plates were coated
using 50 Al/well overnight at 4 8C. For detection of anti-
CD13/APN antibodies, BBMVs in sucrose buffer were
diluted in PBS to a protein concentration of 1.5 mg/ml, and
50 Al/well was used to coat plates overnight at 4 8C.
Blocking of binding of rabbit antibody sc-15360 and rat
monoclonal R3-242 by mouse sera demonstrated specificity
of antibodies in sera of MCMV-infected mice for CD13/
APN. Whole cell ELISAs were also performed to measure
cell surface CD13 expression on the murine cell lines. Cells
were plated at 104 cells/well and incubated with R3-242
anti-CD13 antibody the next day after fixation with 2%
glutaraldehyde. Horseradish peroxidase-conjugated secon-
dary antibodies were used and detected by incubation with
1-Step ABTS (Pierce).Acknowledgments
The author is grateful to Dr. Kenneth Chavin for the
cyclosporine A protocol and Dr. Damir Hamamdzic for
helpful discussions. This research was funded by a grant
from the RGK Foundation.References
Arase, H., Mocarski, E.S., Campbell, A.E., Hill, A.B., Lanier, L.L., 2002.
Direct recognition of cytomegalovirus by activating and inhibitory NK
cell receptors. Science 296 (5571), 1323–1326.
Bartholomaeus, W.N., O’Donoghue, H., Foti, D., Lawson, C.M., Shellam,
G.R., Reed, W.D., 1988. Multiple autoantibodies following cytomega-
lovirus infection: virus distribution and specificity of autoantibodies.
Immunology 64 (3), 397–405.
Berencsi, K., Endresz, V., Klurfeld, D., Kari, L., Kritchevsky, D., Gonczol,
E., 1998. Early atherosclerotic plaques in the aorta following
cytomegalovirus infection of mice. Cell Adhes. Commun. 5 (1), 39–47.
Bhagwat, S.V., Lahdenranta, J., Giordano, R., Arap, W., Pasqualini, R.,
Shapiro, L.H., 2001. CD13/APN is activated by angiogenic signals and
is essential for capillary tube formation. Blood 97 (3), 652–659.
Borchers, A.T., Perez, R., Kaysen, G., Ansari, A.A., Gershwin, M.E., 1999.
Role of cytomegalovirus infection in allograft rejection: a review of
possible mechanisms. Transplant Immunol. 7 (2), 75–82.
Breslin, J.J., Mork, I., Smith, M.K., Vogel, L.K., Hemmila, E.M., Bonavia,
A., Talbot, P.J., Sjostrom, H., Noren, O., Holmes, K.V., 2003. Human
coronavirus 229E: receptor binding domain and neutralization by
soluble receptor at 37 degrees C. J. Virol. 77 (7), 4435–4438.
Brune, W., Hengel, H., Koszinowski, U.H., 1999. A mouse model for
cytomegalovirus infection. In: Coligan, J.E., (Eds.), Current Protocols
in Immunology, vol. Suppl. 32. John Wiley and Sons, Inc., New York,
pp. 19.7.1–19.7.13 (3 vols).
Chen, H., Kinzer, C.A., Paul, W.E., 1996. p161, a murine membrane
protein expressed on mast cells and some macrophages, is mouse
CD13/aminopeptidase N. J. Immunol. 157 (6), 2593–2600.
Cheng, H.M., Khairullah, N.S., 1997. Induction of antiphospholipid
autoantibody during cytomegalovirus infection. Clin. Infect. Dis. 25
(6), 1493–1494.
Curnis, F., Arrigoni, G., Sacchi, A., Fischetti, L., Arap, W., Pasqualini, R.,
L.M. Kasman / Virology 334 (2005) 1–98Corti, A., 2002. Differential binding of drugs containing the NGR motif
to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer
Res. 62 (3), 867–874.
Dubois, N.A., Kolpack, L.C., Wang, R., Azizkhan, R.G., Bautch, V.L.,
1991. Isolation and characterization of an established endothelial cell
line from transgenic mouse hemangiomas. Exp. Cell Res. 196 (2),
302–313.
Fairweather, D., Lawson, C.M., Chapman, A.J., Brown, C.M., Booth, T.W.,
Papadimitriou, J.M., Shellam, G.R., 1998. Wild isolates of murine
cytomegalovirus induce myocarditis and antibodies that cross-react with
virus and cardiac myosin. Immunology 94 (2), 263–270.
Giugni, T.D., Soderberg, C., Ham, D.J., Bautista, R.M., Hedlund, K.O.,
Moller, E., Zaia, J.A., 1996. Neutralization of human cytomegalovi-
rus by human CD13-specific antibodies. J. Infect. Dis. 173 (5),
1062–1071.
Hamamdzic, D., Harley, R.A., Hazen-Martin, D., LeRoy, E.C., 2001.
MCMV induces neointima in IFN-gammaR/ mice: intimal cell
apoptosis and persistent proliferation of myofibroblasts. BMC Muscu-
loskelet. Disord. 2 (1), 3.
Hamamdzic, D., Kasman, L.M., LeRoy, E.C., 2002. The role of infectious
agents in the pathogenesis of systemic sclerosis. Curr. Opin. Rheumatol.
14 (6), 694–698.
Hebart, H., Einsele, H., Klein, R., Fischer, I., Buhler, S., Dietz, K., Jahn, G.,
Berg, P.A., Kanz, L., Muller, C.A., 1996. CMV infection after
allogeneic bone marrow transplantation is associated with the occur-
rence of various autoantibodies and monoclonal gammopathies. Br. J.
Haematol. 95 (1), 138–144.
Hiemstra, H.S., Schloot, N.C., van Veelen, P.A., Willemen, S.J., Franken,
K.L., van Rood, J.J., de Vries, R.R., Chaudhuri, A., Behan, P.O.,
Drijfhout, J.W., Roep, B.O., 2001. Cytomegalovirus in autoimmunity:
T cell crossreactivity to viral antigen and autoantigen glutamic acid
decarboxylase. Proc. Natl. Acad. Sci. U.S.A. 98 (7), 3988–3991.
Homman-Loudiyi, M., Hultenby, K., Britt, W., Soderberg-Naucler, C.,
2003. Envelopment of human cytomegalovirus occurs by budding into
Golgi-derived vacuole compartments positive for gB, Rab 3, Trans-
Golgi network 46, and Mannosidase II. J. Virol. 77 (5), 3191–3203.
Hummel, M., Zhang, Z., Yan, S., DePlaen, I., Golia, P., Varghese, T.,
Thomas, G., Abecassis, M.I., 2001. Allogeneic transplantation induces
expression of cytomegalovirus immediate-early genes in vivo: a model
for reactivation from latency. J. Virol. 75 (10), 4814–4822.
Kawai, M., Hara, Y., Miyazato, I., Hosaki, S., 2001. Novel, aberrantly
truncated isoform of serum CD13 in a family with high serum
aminopeptidase N (CD13) activity. Clin. Chem. 47 (2), 223–230.
Koskinen, P.K., Kallio, E.A., Tikkanen, J.M., Sihvola, R.K., Hayry, P.J.,
Lemstrom, K.B., 1999. Cytomegalovirus infection and cardiac allograft
vasculopathy. Transpl. Infect. Dis. 1 (2), 115–126.
Lawson, C.M., 2000. Evidence for mimicry by viral antigens in animal
models of autoimmune disease including myocarditis. Cell. Mol. Life
Sci. 57 (4), 552–560.
Lee, S.H., Webb, J.R., Vidal, S.M., 2002. Innate immunity to cytomega-
lovirus: the Cmv1 locus and its role in natural killer cell function.
Microbes Infect. 4 (15), 1491–1503.
Lipes, J., Skamene, E., Newkirk, M.M., 2002. The genotype of mice
influences the autoimmune response to spliceosome proteins induced
by cytomegalovirus gB immunization. Clin. Exp. Immunol. 129 (1),
19–26.
Lunardi, C., Bason, C., Navone, R., Millo, E., Damonte, G., Corrocher, R.,
Puccetti, A., 2000. Systemic sclerosis immunoglobulin G autoanti-
bodies bind the human cytomegalovirus late protein UL94 and induce
apoptosis in human endothelial cells. Nat. Med. 6 (10), 1183–1186.
Matthes-Martin, S., Aberle, S.W., Peters, C., Holter, W., Popow-Kraupp, T.,
Potschger, U., Fritsch, G., Ladenstein, R., Rosenmayer, A., Dieckmann,
K., Gadner, H., 1998. CMV-viraemia during allogenic bone marrow
transplantation in paediatric patients: association with survival and
graft-versus-host disease. Bone Marrow Transplant. 21 (Suppl. 2),
S53–S56.
Michelson, S., Tardy-Panit, M., Colimon, R., Landini, M.P., 1989. Ahuman cytomegalovirus-neutralizing monoclonal antibody recognizes a
normal cell protein. J. Gen. Virol. 70 (Pt. 3), 673–684.
Naucler, C.S., Larsson, S., Moller, E., 1996. A novel mechanism for virus-
induced autoimmunity in humans. Immunol. Rev. 152, 175–192.
Nieto, F.J., Adam, E., Sorlie, P., Farzadegan, H., Melnick, J.L., Comstock,
G.W., Szklo, M., 1996. Cohort study of cytomegalovirus infection as a
risk factor for carotid intimal-medial thickening, a measure of
subclinical atherosclerosis. Circulation 94 (5), 922–927.
O’Connell, K.A., Edidin, M., 1990. A mouse lymphoid endothelial cell line
immortalized by simian virus 40 binds lymphocytes and retains
functional characteristics of normal endothelial cells. J. Immunol. 144
(2), 521–525.
Pandey, J.P., LeRoy, E.C., 1998. Human cytomegalovirus and the
vasculopathies of autoimmune diseases (especially scleroderma),
allograft rejection, and coronary restenosis. Arthritis Rheum. 41 (1),
10–15.
Pasqualini, R., Koivunen, E., Kain, R., Lahdenranta, J., Sakamoto, M.,
Stryhn, A., Ashmun, R.A., Shapiro, L.H., Arap, W., Ruoslahti, E.,
2000. Aminopeptidase N is a receptor for tumor-homing peptides and a
target for inhibiting angiogenesis. Cancer Res. 60 (3), 722–727.
Phillips, A.J., Tomasec, P., Wang, E.C., Wilkinson, G.W., Borysiewicz,
L.K., 1998. Human cytomegalovirus infection downregulates expres-
sion of the cellular aminopeptidases CD10 and CD13. Virology 250 (2),
350–358.
Plakidou-Dymock, S., Tanner, M.J., McGivan, J.D., 1993. A role for
aminopeptidase N in Na(+)-dependent amino acid transport in bovine
renal brush-border membranes. Biochem. J. 290 (Pt. 1), 59–65.
Presti, R.M., Pollock, J.L., Dal Canto, A.J., O’Guin, A.K., Virgin, H.W.t.,
1998. Interferon gamma regulates acute and latent murine cytomega-
lovirus infection and chronic disease of the great vessels. J. Exp. Med.
188 (3), 577–588.
Riemann, D., Kehlen, A., Langner, J., 1999. CD13—Not just a marker in
leukemia typing. Immunol. Today 20 (2), 83–88.
Soderberg, C., Giugni, T.D., Zaia, J.A., Larsson, S., Wahlberg, J.M.,
Moller, E., 1993a. CD13 (human aminopeptidase N) mediates human
cytomegalovirus infection. J. Virol. 67 (11), 6576–6585.
Soderberg, C., Larsson, S., Bergstedt-Lindqvist, S., Moller, E., 1993b.
Definition of a subset of human peripheral blood mononuclear cells that
are permissive to human cytomegalovirus infection. J. Virol. 67 (6),
3166–3175.
Soderberg, C., Larsson, S., Rozell, B.L., Sumitran-Karuppan, S., Ljung-
man, P., Moller, E., 1996a. Cytomegalovirus-induced CD13-specific
autoimmunity—A possible cause of chronic graft-vs-host disease.
Transplantation 61 (4), 600–609.
Soderberg, C., Sumitran-Karuppan, S., Ljungman, P., Moller, E., 1996b.
CD13-specific autoimmunity in cytomegalovirus-infected immunocom-
promised patients. Transplantation 61 (4), 594–600.
Stoddart, C.A., Cardin, R.D., Boname, J.M., Manning, W.C., Abenes, G.B.,
Mocarski, E.S., 1994. Peripheral blood mononuclear phagocytes
mediate dissemination of murine cytomegalovirus. J. Virol. 68 (10),
6243–6253.
Swihart, K., Fruth, U., Messmer, N., Hug, K., Behin, R., Huang, S., Del
Giudice, G., Aguet, M., Louis, J.A., 1995. Mice from a genetically
resistant background lacking the interferon gamma receptor are
susceptible to infection with Leishmania major but mount a polarized
T helper cell 1-type CD4+ T cell response. J. Exp. Med. 181 (3),
961–971.
Tirado, S.M., Yoon, K.J., 2003. Antibody-dependent enhancement of virus
infection and disease. Viral Immunol. 16 (1), 69–86.
Vijgen, L., Keyaerts, E., Zlateva, K., Van Ranst, M., 2004. Identification of
six new polymorphisms in the human coronavirus 229E receptor gene
(aminopeptidase N/CD13). Int. J. Infect. Dis. 8 (4), 217–222.
Wang, X., Huong, S.M., Chiu, M.L., Raab-Traub, N., Huang, E.S., 2003.
Epidermal growth factor receptor is a cellular receptor for human
cytomegalovirus. Nature 424 (6947), 456–461.
Watanabe, S., 1998. The receptor and pathways for human cytomegalovirus
entry. Nippon Rinsho 56 (1), 44–49.
L.M. Kasman / Virology 334 (2005) 1–9 9Wentworth, D.E., Holmes, K.V., 2001. Molecular determinants of
species specificity in the coronavirus receptor aminopeptidase N
(CD13): influence of N-linked glycosylation. J. Virol. 75 (20),
9741–9752.
Wright, J.F., Kurosky, A., Pryzdial, E.L., Wasi, S., 1995. Host cellular
annexin II is associated with cytomegalovirus particles isolated from
cultured human fibroblasts. J. Virol. 69 (8), 4784–4791.
Yeager, C.L., Ashmun, R.A., Williams, R.K., Cardellichio, C.B., Shapiro,L.H., Look, A.T., Holmes, K.V., 1992. Human aminopeptidase N is a
receptor for human coronavirus 229E. Nature 357 (6377), 420–422.
Yu, X.J., Luo, C., Lin, J.C., Hao, P., He, Y.Y., Guo, Z.M., Qin, L., Su, J.,
Liu, B.S., Huang, Y., Nan, P., Li, C.S., Xiong, B., Luo, X.M., Zhao,
G.P., Pei, G., Chen, K.X., Shen, X., Shen, J.H., Zou, J.P., He, W.Z., Shi,
T.L., Zhong, Y., Jiang, H.L., Li, Y.X., 2003. Putative hAPN receptor
binding sites in SARS_CoV spike protein. Acta Pharmacol. Sin. 24 (6),
481–488.
